Palbociclib (PD-0332991) HCl

Licensed by Pfizer 製品コードS1116

Palbociclib (PD-0332991) HCl化学構造

分子量(MW):483.99

Palbociclib (PD-0332991) HClは一種の高度選択性的なCDK4/6阻害剤で、無細胞試験でIC50値が11nM/16nMですが、CDK1/2/5、EGFR、FGFR、PDGFRとInsR等に抑制活性を表しません。臨床3期。

サイズ 価格(税別)  
JPY 18260.00
JPY 28220.00
JPY 94620.00

カスタマーフィードバック(8)

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  •  

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

    WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

    P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

製品安全説明書

CDK阻害剤の選択性比較

生物活性

製品説明 Palbociclib (PD-0332991) HClは一種の高度選択性的なCDK4/6阻害剤で、無細胞試験でIC50値が11nM/16nMですが、CDK1/2/5、EGFR、FGFR、PDGFRとInsR等に抑制活性を表しません。臨床3期。
特性 Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
ターゲット
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
体外試験

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 MlPyT4lv[XOnIFHzd4F6 MVuyOEBp MXvJcohq[mm2aX;uJI9nKEOGS{SgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDSZkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECyJO69VQ>? M17S[lI1PjRzMUCz
COLO205 M3HvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[w[VBlPzJiaB?= NGjIUGNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEO2JO69VQ>? NGS2NYgzPDZ2MUGwNy=>
U937 MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvzO|IhcA>? NV7BR4g6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkG0JO69VQ>? M{n0[VI1PjRzMUCz
MOLM13 NFHSZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv4bFY4OiCq MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTF2xN{Bk\WyuczDoZZJjd3KrbnegSmxVOyCLVFSgcZV1[W62IHHzd4V{e2WmIHHzJIlv[2:{cH;yZZRqd25ib3[gX|NJZXSqeX3p[Ilv\SCrboTvJGRPSSC5aYToJGlEPTBib3[gNE4xQTZizszN NXf3[pF5OjR4NEGxNFM>
MOLM13 M1HrfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHJO|IhcA>? NFjqRmFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJNwemGoZX7pZk1z\XOrc4ThcpQhcHWvYX6gUW9NVTF|IHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ49zeG:{YYTpc44hd2ZiW{PIYZRpgW2rZHnu[UBqdnSxIFTORUB4cXSqIFnDOVAhd2ZiMD6wPVYh|ryP M4j0d|I1PjRzMUCz
MDA-MB-435 MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq4fld[OjRiaB?= NFnQOnNKSzVyPUCuNVYh|ryP NYDr[GJEOTV6MEG4N|E>
K562 MWXDfZRwfG:6aXOgRZN{[Xl? NUXMfHFTQTZiaB?= M3LMZmROW09? Mo\uTWM2OD1{IN88US=> NW\5S5NWOjR2MUe1OlY>
DU145 NWrmRow1S3m2b4TvfIlkKEG|c3H5 NIfQVGg6PiCq M4DjWmROW09? NWDKNJFjUUN3ME23MlUh|ryP NHrqRXEzPDRzN{W2Oi=>
MDA-MB-231 NFLPcGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fGbVEh|ryP M{X4fVI1KGh? NXK2XXN[TE2VTx?= M2HPRWNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEBIOSCyaHHz[S=> NFS2[3kzPDRzN{W2Oi=>
MCF7 NVzmSIg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVniUpBJOSEQvF2= Ml7aNlQhcA>? NV\Hb4VqTE2VTx?= NWXUe4JOS2WubDDjfYNt\SCjcoLld5Qh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNm MnPKNlQ1OTd3Nk[=
MCF7 M3LTeGtqdmG|ZTDBd5NigQ>? NXTrNHN3PSEQvF2= NGe1fFYzPCCq MXPEUXNQ NI\vUY9KdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG|dH;tZUBxcG:|cHjvdplt[XSrb36gZZQhW2W{N{iw M4jXVlI1PDF5NU[2
MDA-MB-231 M1fUfWtqdmG|ZTDBd5NigQ>? NUW5bIhPPSEQvF2= NHnqZ|czPCCq M2PqOWROW09? NVLMS|NGUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=> NF7GVFkzPDRzN{W2Oi=>
MDA-MB-231 MUHGeY5kfGmxbjDBd5NigQ>? NXT0doxbOS1zMDFOwG0> MV:yOEBp NGLwWpdFVVOR Mlvv[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[Wen NIrVS4IzPDRzN{W2Oi=>
MCF7 M{PySWZ2dmO2aX;uJGF{e2G7 MWmxMVExKM7:TR?= NHnJdlMzPCCq MVzEUXNQ M{XrPYRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZR?= M1iwRVI1PDF5NU[2
MDA-MB-231 NXj3ZnpvTnWwY4Tpc44hSXO|YYm= M1H4S|AvPS1zIN88US=> M1Pje|Q5KGh? NW\zelZjTE2VTx?= MVjoZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=> NWLRdHFqOjR2MUe1OlY>
MCF7 MnX1SpVv[3Srb36gRZN{[Xl? MUGwMlUuOSEQvF2= M3;UO|Q5KGh? MmrISG1UVw>? NGPtR2dp[XNibn:gR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JJN2[i2JMTDwbIF{\Q>? NFnGbZUzPDRzN{W2Oi=>
697 MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF2OD6zPEBvVQ>? NY\SOWZOW0GQR1XS
P12-ICHIKAWA NFX6XpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTl4LkC0JI5O NE\SUWlUSU6JRWK=
NB69 NUDTdY9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTUfmpVUUN3ME2xOlEvQCCwTR?= MV7TRW5ITVJ?
EoL-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF6Nz6yOkBvVQ>? NWLG[297W0GQR1XS
BHT-101 NEGwNZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfoTWM2OD1zOUiuNlUhdk1? NX;Fb|hvW0GQR1XS
SK-NEP-1 M{e2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q0OWlEPTB;MkKwMlAzKG6P MnG2V2FPT0WU
MHH-NB-11 M{TleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnWwTWM2OD1{MkCuNVkhdk1? NILzVIlUSU6JRWK=
AsPC-1 M3vNRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\xeo1KSzVyPUK1Nk42OyCwTR?= M4HYT3NCVkeHUh?=
ES1 Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\wTWM2OD1{NU[uNlUhdk1? M{LxbXNCVkeHUh?=
LAMA-84 M{HyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS4TWM2OD1{NUiuNVkhdk1? M1[0O3NCVkeHUh?=
MOLT-16 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDJWlJKSzVyPUK1PE41QSCwTR?= MV7TRW5ITVJ?
ES7 NGLMW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LWZWlEPTB;MkezMlA6KG6P NYjnO|lZW0GQR1XS
KY821 MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHO[4x7UUN3ME2zNVQvOSCwTR?= Mk\TV2FPT0WU
RT-112 M1;PWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHrTWM2OD1|MkGuNFUhdk1? MWHTRW5ITVJ?
HL-60 NV;sdnYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn2W4lpUUN3ME2zOFAvPjZibl2= M3\KfHNCVkeHUh?=
MOLT-4 MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvHTWM2OD1|NEWuNVMhdk1? NF;sPGNUSU6JRWK=
KARPAS-45 NX;ndpJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;CeGlEPTB;M{e2MlE3KG6P MorSV2FPT0WU
SK-N-AS NYfsWHpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWSz[HNQUUN3ME2zPFcvQDNibl2= MYjTRW5ITVJ?
CTB-1 NVL6W3FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTRyNT6wNkBvVQ>? NX7mUWFwW0GQR1XS
NKM-1 M2jmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV75RWNiUUN3ME20NVEvQDlibl2= NY[4VoNVW0GQR1XS
HTC-C3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rlSGlEPTB;NEOyMlk2KG6P Mo\qV2FPT0WU
BE-13 NFjjSXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTR2ND6yO{BvVQ>? MV3TRW5ITVJ?
KOSC-2 M37vZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXxN4tKSzVyPUS2Ok46KG6P MlKyV2FPT0WU
NB14 M{jOS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjqTWM2OD12OEOuOVghdk1? MVrTRW5ITVJ?
CAL-27 MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzlSJFjUUN3ME20PVQvPTlibl2= NEXKXYtUSU6JRWK=
H9 NGT2SFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlL3TWM2OD12OUWuOFMhdk1? M2S4WHNCVkeHUh?=
RS4-11 Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTVyND63N{BvVQ>? NWj6cI1wW0GQR1XS
PA-1 M3TofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2j1PGlEPTB;NUC5Mlg3KG6P MUHTRW5ITVJ?
MV-4-11 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTVzMz64OUBvVQ>? M1rNVHNCVkeHUh?=
OS-RC-2 M3vyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDITWM2OD13MkGuOlIhdk1? MV7TRW5ITVJ?
RPMI-8226 NUfoW21qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\SOmlEPTB;NUK2Mlg3KG6P NFXTV2RUSU6JRWK=
HGC-27 MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofNTWM2OD13NkSuPVkhdk1? MXHTRW5ITVJ?
CHP-212 NX7TXo9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:xPGlEPTB;NUmzMlU6KG6P NXnj[2FrW0GQR1XS
NB10 MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv6TWM2OD13OUmuNVghdk1? NXz5collW0GQR1XS
HH NIDkbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe2PZdKSzVyPUW5PU41OyCwTR?= M2XoNnNCVkeHUh?=
EW-16 MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTZyMz61NkBvVQ>? MkHRV2FPT0WU
ES8 NHzLU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nNPWlEPTB;NkC1MlIyKG6P NHPvOJdUSU6JRWK=
HAL-01 MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDCSWF7UUN3ME22NFUvPjdibl2= NVzEeoxSW0GQR1XS
A204 NFzkRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonFTWM2OD14M{OuPVEhdk1? NXjsZ5c{W0GQR1XS
MHH-PREB-1 NEnxbZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTZ|Nj65PUBvVQ>? NWi0cGVkW0GQR1XS
EM-2 NI\vPVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYruZoNDUUN3ME22OVAvPjRibl2= NV3DNZlwW0GQR1XS
BV-173 NYfMO2NsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTZ3Mj60PEBvVQ>? NUnROpY4W0GQR1XS
ONS-76 NIO0[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknGTWM2OD14N{euPFIhdk1? M3PzTXNCVkeHUh?=
KM-H2 M2W3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly5TWM2OD14OUWuOVQhdk1? NELxdI9USU6JRWK=
D-263MG NV;IPVY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPSTWM2OD15MUeuNVIhdk1? NIjhenBUSU6JRWK=
ES3 NWS0O2dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTd{OD65N{BvVQ>? NYHXU3hyW0GQR1XS
VA-ES-BJ MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTd|Mj6yO{BvVQ>? NXXNVXdxW0GQR1XS
NBsusSR M2jXZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvhTWM2OD15NEKuPVkhdk1? NULvbYx7W0GQR1XS
NCI-H520 M2S1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTd2Nj61NkBvVQ>? MnyzV2FPT0WU
ES5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7ITWM2OD15NUKuPEBvVQ>? M{PGeXNCVkeHUh?=
T-24 NEjHNplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmWzTWM2OD15N{iuO|Ehdk1? M3;wb3NCVkeHUh?=
SW962 Mly2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3KdWRRUUN3ME24NFgvPjNibl2= Mm\mV2FPT0WU
EW-3 NYnPSG5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzRV5RCUUN3ME24NFgvPzZibl2= NF\NXGZUSU6JRWK=
RXF393 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\HTWM2OD16MUKuO|khdk1? MVrTRW5ITVJ?
U251 MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfXSYxKSzVyPUixN{45QCCwTR?= Mn3uV2FPT0WU
CAMA-1 NEfY[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf6VJBEUUN3ME24N|MvQTRibl2= NVrEenkzW0GQR1XS
JVM-3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPpVotmUUN3ME24OVEvPzhibl2= NXnNTnlLW0GQR1XS
COLO-800 NWnyUocxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTh7Nz63PEBvVQ>? NFPHOlRUSU6JRWK=
OVCAR-5 NXW4fW5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TaOWlEPTB;OUCwMlEhdk1? NEnK[IRUSU6JRWK=
LB1047-RCC NYnVc3FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrjTWM2OD17MkeuOVYhdk1? NXnMbXBOW0GQR1XS
SW954 NWi1N2M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3lTWM2OD17MkmuOFEhdk1? M1nLcXNCVkeHUh?=
J-RT3-T3-5 M173Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4P3TWlEPTB;OUO2MlA3KG6P MWPTRW5ITVJ?
Mewo NWX1eHVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLwfYFKSzVyPUmzOk43KG6P NWW5RVFsW0GQR1XS
NCI-H1770 MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1uyfWlEPTB;OUSwMlU2KG6P M{\IR3NCVkeHUh?=
HO-1-N-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTl4Mj64NUBvVQ>? Mn3MV2FPT0WU
HSC-3 MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLJTWM2OD17Nk[uOFghdk1? M4rBcHNCVkeHUh?=
TYK-nu MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL6[HpKSzVyPUm5PE4zPSCwTR?= NVr0VZJJW0GQR1XS
KYSE-150 M2nvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjyXG9KSzVyPUGuNFAxPzZizszN NIHKbpVUSU6JRWK=
SN12C NEXofVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLTbXlsUUN3ME2xMlAxQDd3IN88US=> MVTTRW5ITVJ?
MOLT-13 NWHESINYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn23TWM2OD1zLkCxOFIyKM7:TR?= MmLOV2FPT0WU
TE-11 M{fuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXJTWM2OD1zLkC0PFEzKM7:TR?= MVTTRW5ITVJ?
DB MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTFwMEeyO|Mh|ryP NGDkeHRUSU6JRWK=
CAL-39 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MormTWM2OD1zLkC3OVIzKM7:TR?= MVLTRW5ITVJ?
A3-KAW NYe5VZpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfaNnM6UUN3ME2xMlA5PDB6IN88US=> NXTwe5plW0GQR1XS
CHP-134 M13SVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jVcmlEPTB;MT6xNVgxPyEQvF2= M3TMOXNCVkeHUh?=
TGW NX3acoluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFwMUKzPVUh|ryP NUXrNFdSW0GQR1XS
QIMR-WIL NETYW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HRcmlEPTB;MT6xN|E{PCEQvF2= MnLPV2FPT0WU
NCI-SNU-1 NX23O3hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFwMU[zOVQh|ryP NXPWSVl4W0GQR1XS
CGTH-W-1 NICyZ5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT3eIRKSzVyPUGuNVcyQDZizszN NGDVUY1USU6JRWK=
MHH-ES-1 M4Xwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fQZWlEPTB;MT6xO|k5PiEQvF2= NH\hWJZUSU6JRWK=
LB2241-RCC NF7Fb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\YW2lEPTB;MT6xPFYzKM7:TR?= NX7tOmwzW0GQR1XS
ML-2 M2q1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfpTWM2OD1zLkKwO|M1KM7:TR?= M2nWbnNCVkeHUh?=
COR-L23 NFLMcnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTFwMkK5N|Mh|ryP NWPxXpM3W0GQR1XS
BFTC-905 MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXqzeY51UUN3ME2xMlI1OjZ5IN88US=> NXLnXJRVW0GQR1XS
Hs-578-T NH3SXlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HxT2lEPTB;MT6yOVgyPyEQvF2= M3LoZ3NCVkeHUh?=
KG-1 NGrob4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37sVmlEPTB;MT6yOlY5PiEQvF2= MWXTRW5ITVJ?
HEL NX;PPJJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFwMkmzN|gh|ryP NYTFfVVJW0GQR1XS
A549 MmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTFwMkmzPVkh|ryP MkLoV2FPT0WU
COLO-741 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zOOGlEPTB;MT6zNlA5QSEQvF2= M{nCWnNCVkeHUh?=
PC-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDLTWM2OD1zLkO1NlIyKM7:TR?= MX;TRW5ITVJ?
HOS MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;5SZpKSzVyPUGuN|UzQTZizszN MUHTRW5ITVJ?
HT-1080 NYjYSmhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P4UmlEPTB;MT6zO|UyQSEQvF2= NH7pcYxUSU6JRWK=
TE-8 NYi5WVNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fEZmlEPTB;MT60NVc4PCEQvF2= MYHTRW5ITVJ?
BHY NWK5eFZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnUUHhIUUN3ME2xMlQ3QTJ|IN88US=> MWHTRW5ITVJ?
BB65-RCC M4fKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:2WXZKSzVyPUGuOVA2OjhizszN M2Ls[nNCVkeHUh?=
HN MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f1cGlEPTB;MT61OFA4OSEQvF2= NIr0[pBUSU6JRWK=
NCI-H441 NWn5d2dCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT1d|lyUUN3ME2xMlU1QTB5IN88US=> NEnwdIJUSU6JRWK=
RPMI-8866 NGrUWVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj6XWdvUUN3ME2xMlU5PTB5IN88US=> NVe1em9FW0GQR1XS
CAL-62 MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLSdZAxUUN3ME2xMlYxQDZ{IN88US=> M3vzTHNCVkeHUh?=
MG-63 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\YSXVKSzVyPUGuOlE5OTNizszN NYfPXYgxW0GQR1XS
SK-LU-1 Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHQTWM2OD1zLk[yNVUzKM7:TR?= NWLRcpE6W0GQR1XS
BCPAP MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInJRWZKSzVyPUGuOlY1PTdizszN M1\2XnNCVkeHUh?=
22RV1 NFmxPIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEGxN41KSzVyPUGuOlc5PDNizszN MULTRW5ITVJ?
T47D Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFwNkiwOlEh|ryP M3jhNnNCVkeHUh?=
MSTO-211H NVfjdIxQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[zOWlEPTB;MT62PVYxOyEQvF2= NI\5[FVUSU6JRWK=
DEL MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFwN{CyO|Mh|ryP Mn7yV2FPT0WU
H4 MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL5TWM2OD1zLkezNlEzKM7:TR?= M1m4T3NCVkeHUh?=
CAL-51 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvxTWM2OD1zLke0PFU2KM7:TR?= NGrJboRUSU6JRWK=
ABC-1 NISyUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj5TWM2OD1zLke4OVgzKM7:TR?= M2rOWHNCVkeHUh?=
MZ2-MEL M4nX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LnXWlEPTB;MT63PVU1OiEQvF2= MWfTRW5ITVJ?
YKG-1 M1vqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO2XowyUUN3ME2xMlgyODZzIN88US=> MUnTRW5ITVJ?
KM12 NHXBS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7UVXdwUUN3ME2xMlgyPjB{IN88US=> NY\wcpR6W0GQR1XS
L-363 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HE[2lEPTB;MT64O|QyOiEQvF2= NGq4fFVUSU6JRWK=
KU812 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTFwOEmyPFIh|ryP MYDTRW5ITVJ?
LOXIMVI MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUOzO4IyUUN3ME2xMlkyOjJ6IN88US=> NV3rUllPW0GQR1XS
G-401 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3WWXRKSzVyPUGuPVI1OjhizszN MX;TRW5ITVJ?
SW780 M3XFRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PV[WlEPTB;MT65OlI1PiEQvF2= MnvBV2FPT0WU
SW872 M1K3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S5ZWlEPTB;MT65PFM{KM7:TR?= Mk[5V2FPT0WU
NB7 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLiTWM2OD1zLkm5N|I{KM7:TR?= NG\Q[WhUSU6JRWK=
T98G NGPDVppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJwMEC2OlYh|ryP M3KxRnNCVkeHUh?=
SW1710 MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvlVphjUUN3ME2yMlA3QTR3IN88US=> MWTTRW5ITVJ?
NCI-H1573 Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPnTWM2OD1{LkC3Nlk5KM7:TR?= MkfrV2FPT0WU
KE-37 NIDZOJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfS[WllUUN3ME2yMlA5QTVzIN88US=> NGG5WlRUSU6JRWK=
786-0 MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XWdGlEPTB;Mj6xOVQ{QSEQvF2= M1T2XXNCVkeHUh?=
SAS Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\vS|dnUUN3ME2yMlIxOzd2IN88US=> MYHTRW5ITVJ?
CAL-54 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJwMkC0NVMh|ryP M2T3cHNCVkeHUh?=
SF268 MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;TTWM2OD1{LkKzNVIzKM7:TR?= M3ToXnNCVkeHUh?=
SW620 M13MSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XUVGlEPTB;Mj6yOlE3QSEQvF2= NWTwcXVrW0GQR1XS
MN-60 M{LVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX0fphKSzVyPUKuN|ExPiEQvF2= MoTzV2FPT0WU
EFO-27 NGfkbVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHwTnBKSzVyPUKuN|IxPThizszN NV7WeZlSW0GQR1XS
NCI-H747 M4W1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXkTWM2OD1{LkOyNVk6KM7:TR?= NXTke|JJW0GQR1XS
HCC2218 NXLGeXlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13MZ2lEPTB;Mj6zOVM4PCEQvF2= M3\UbXNCVkeHUh?=
MIA-PaCa-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJwM{[0N|ch|ryP NUfTendOW0GQR1XS
SJSA-1 NIf6[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJwM{e3PVYh|ryP Ml7kV2FPT0WU
RKO NWi4WIhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLVTIdzUUN3ME2yMlM5PDl4IN88US=> MXnTRW5ITVJ?
NB6 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPk[mhKSzVyPUKuOFA{PzRizszN M374fXNCVkeHUh?=
ES4 NILa[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXiyUGZVUUN3ME2yMlQ2PDJ{IN88US=> NWX5WI1SW0GQR1XS
EGI-1 NYL1dIlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHyd2VEUUN3ME2yMlQ3QDh|IN88US=> MYLTRW5ITVJ?
CTV-1 M3fEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJwNUK3O|Mh|ryP NWDITGhjW0GQR1XS
NCI-H1355 NX7TZ2pYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\qTWM2OD1{LkW1PVUyKM7:TR?= NFm0cGJUSU6JRWK=
GT3TKB NUjWZWZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XUdmlEPTB;Mj61PVE6QSEQvF2= MYHTRW5ITVJ?
SK-HEP-1 M4nCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofXTWM2OD1{LkW5NlY3KM7:TR?= NHzKVWlUSU6JRWK=
GAMG M{nUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJwNUmzPVQh|ryP MYjTRW5ITVJ?
SK-MES-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;I[GRmUUN3ME2yMlYyQDB|IN88US=> MnfIV2FPT0WU
RO82-W-1 NF:wZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTJwNkKwOVch|ryP MoW5V2FPT0WU
ECC10 NVXqSVRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fvUWlEPTB;Mj63NFIxPiEQvF2= NY\rd5NMW0GQR1XS
MCF7 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJwN{G0OlQh|ryP M{LkOHNCVkeHUh?=
D-283MED NYP1cIlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vpbGlEPTB;Mj63NlQ{KM7:TR?= Ml7vV2FPT0WU
RPMI-7951 M4XzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\udVVKSzVyPUKuO|U3QTRizszN M3XyXHNCVkeHUh?=
Ramos-2G6-4C10 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TKXmlEPTB;Mj63O|A6QSEQvF2= NUjwVZExW0GQR1XS
KGN M3[2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H5R2lEPTB;Mj64NVg5PCEQvF2= MYfTRW5ITVJ?
NUGC-3 MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3HWVJKSzVyPUKuPFI2ODVizszN NHy2OoRUSU6JRWK=
NCI-H292 NF6wbZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzYNnFVUUN3ME2yMlg2ODV|IN88US=> M2jYVHNCVkeHUh?=
Becker MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJwOUW4N|Ih|ryP Mo\qV2FPT0WU
NCI-H1299 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rCWWlEPTB;Mz6wOVI3OyEQvF2= M3OyTHNCVkeHUh?=
ETK-1 NHzJ[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\SeWlEPTB;Mz6wOVQ{KM7:TR?= MmjBV2FPT0WU
TK10 NHS3XoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm2TWM2OD1|LkKwNVY2KM7:TR?= MWHTRW5ITVJ?
VMRC-RCZ NVLQT4Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTNwM{[0PFgh|ryP MlmxV2FPT0WU
YH-13 M3;lVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPoTWM2OD1|LkS0NFc6KM7:TR?= MmHWV2FPT0WU
DU-145 Mn;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjibHpKSzVyPUOuOFYzPjlizszN NV\6S4FmW0GQR1XS
SW1088 NIW2fVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vHNGlEPTB;Mz60O|Q4KM7:TR?= NIDKVVJUSU6JRWK=
HOP-92 MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfiPYVKSzVyPUOuOVA{PDJizszN NHS1UHBUSU6JRWK=
KP-N-YS M1fZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfxbGF{UUN3ME2zMlYzOTN7IN88US=> NGDVVpdUSU6JRWK=
NCI-H460 MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK2[XZKSzVyPUOuOlY4OyEQvF2= MoLVV2FPT0WU
U-2-OS NUjpTHBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TRb2lEPTB;Mz63NlU{PSEQvF2= NFOyUnVUSU6JRWK=
A101D M1LIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPybWhKSzVyPUOuO|Y6OzZizszN M2LaT3NCVkeHUh?=
MDA-MB-231 NHnRW29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPxTWM2OD1|LkixPVUyKM7:TR?= NEnLSplUSU6JRWK=
IST-MES1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTNwOEOyJO69VQ>? M{\YO3NCVkeHUh?=
COR-L105 NEjJbIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XnSWlEPTB;ND6wNVgh|ryP NF71cW9USU6JRWK=
NCI-H1437 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrORo1KSzVyPUSuNFI{ODJizszN M2ixVHNCVkeHUh?=
CAL-85-1 M{jNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fTS2lEPTB;ND6wNlQ3OSEQvF2= NFvZRlVUSU6JRWK=
MZ1-PC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3SwWWlEPTB;ND6xPFU2PiEQvF2= M1[2UXNCVkeHUh?=
VM-CUB-1 NFfnTYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTRwM{GyPFQh|ryP MnLkV2FPT0WU
CHL-1 NIHKcWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vpc2lEPTB;ND6zNlE3QSEQvF2= NFe5ZmpUSU6JRWK=
MDA-MB-361 M3riRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPSS25IUUN3ME20MlM{OTV|IN88US=> M1v0Z3NCVkeHUh?=
NCI-H661 NYTBNnhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;DT3JKSzVyPUSuOVAxQTJizszN NYjxfYJnW0GQR1XS
EW-11 M3\UOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTRwNUKyN|Eh|ryP NYLNZ2tuW0GQR1XS
BEN Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTRwNUK4NVUh|ryP NWqzS2l4W0GQR1XS
BFTC-909 M1Swemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjPcVNKSzVyPUSuOVYzPzVizszN NGnObY9USU6JRWK=
NCI-H2087 NHHGXFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHW3[GZKSzVyPUSuOVgyPjRizszN NFnzNXdUSU6JRWK=
RVH-421 MoG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUOyO|E2UUN3ME20MlY3PjlizszN M1rP[nNCVkeHUh?=
P30-OHK MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTRwNkiwNFgh|ryP MofzV2FPT0WU
NCI-H28 M1jjXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmGyTWM2OD12LkixOlYyKM7:TR?= NIe0NJJUSU6JRWK=
ES6 NHXNUVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnqfGFTUUN3ME20Mlg{ODF4IN88US=> NXfqXI8xW0GQR1XS
769-P MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTRwOEW5NlYh|ryP M2P6eXNCVkeHUh?=
OE33 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTRwOEixOlEh|ryP MnjuV2FPT0WU
SW982 M{TIN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTRwOUWwOlEh|ryP M2W1WnNCVkeHUh?=
A388 M{jDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfne2VXUUN3ME21MlAzQTh|IN88US=> MUnTRW5ITVJ?
TI-73 M3LyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHiTWM2OD13LkC2NVk1KM7:TR?= MWrTRW5ITVJ?
HCT-116 NF3RfXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTVwMEm4PFkh|ryP MkLLV2FPT0WU
HuP-T3 M2jsU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\PSWlEPTB;NT6xPFcxQSEQvF2= M3HjdXNCVkeHUh?=
G-402 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmf5TWM2OD13LkG5OFE3KM7:TR?= NFHXc5lUSU6JRWK=
NCI-H1792 NWLBZlk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYW2c4gzUUN3ME21MlI1PjJ{IN88US=> MlvMV2FPT0WU
NCI-H209 NGjrSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTVwMkW5OFIh|ryP MlL0V2FPT0WU
NCI-H1650 NEX2NmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTVwM{C2N|Qh|ryP MVXTRW5ITVJ?
LCLC-97TM1 NV3pUXJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7mOZhpUUN3ME21MlMyQDB6IN88US=> M3TEbXNCVkeHUh?=
S-117 M4LaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnhV3dDUUN3ME21MlM3QTd4IN88US=> MXnTRW5ITVJ?
GI-ME-N M4HuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n3[2lEPTB;NT6zPVY5OSEQvF2= MUfTRW5ITVJ?
NCI-H2122 MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33ySmlEPTB;NT60PVM6PyEQvF2= M{LCOnNCVkeHUh?=
NCI-H1793 M1XFc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2H4eGlEPTB;NT62O|U6OyEQvF2= MX7TRW5ITVJ?
C2BBe1 MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LrTmlEPTB;NT63NFA5QCEQvF2= MlzwV2FPT0WU
TE-12 MmTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrKSpFKSzVyPUWuPFA2PTZizszN M3\3cXNCVkeHUh?=
LCLC-103H NWPObWRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTVwOUG3JO69VQ>? M1u2TnNCVkeHUh?=
A673 MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTVwOUG5N|Ih|ryP NWrxdoxvW0GQR1XS
BB30-HNC NV73SphHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmKyTWM2OD13Lkm4N|Yh|ryP NFzVdm5USU6JRWK=
SF295 M1XDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Wz[mlEPTB;Nj6wNFQzOiEQvF2= MVLTRW5ITVJ?
KU-19-19 M2TpOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEGyN4NKSzVyPU[uNFE4OzFizszN MULTRW5ITVJ?
CFPAC-1 MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTpTpNQUUN3ME22MlA1PDR|IN88US=> NF:zd4dUSU6JRWK=
LoVo M3jnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X4O2lEPTB;Nj6wOVA3OyEQvF2= NXTwXZV2W0GQR1XS
8505C MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGeyV49KSzVyPU[uNFc2PzNizszN MoHsV2FPT0WU
GMS-10 NVXHd4xCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37t[mlEPTB;Nj6xOVAxOiEQvF2= MYfTRW5ITVJ?
Ca9-22 NVG3SZJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\nPGNVUUN3ME22MlE3PzFizszN NVr3T5VsW0GQR1XS
DOK MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jlNmlEPTB;Nj6yNlA4OiEQvF2= Mn\YV2FPT0WU
FADU Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTZwMk[wN|kh|ryP MnPuV2FPT0WU
BxPC-3 M{fYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkmyTWM2OD14LkK3N|Ih|ryP NVXSPWp7W0GQR1XS
CAL-33 NUHNZlE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm2R4tLUUN3ME22MlI6OjBzIN88US=> NF:wUVVUSU6JRWK=
SHP-77 NGDMTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTZwM{G1NVIh|ryP NGLCdZlUSU6JRWK=
LXF-289 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTZwM{O0OVUh|ryP NVft[VdzW0GQR1XS
GB-1 NGn3eGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrRTYlKSzVyPU[uN|gzKM7:TR?= NW\Rd2sxW0GQR1XS
KS-1 MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXxTWM2OD14LkO4OFQ4KM7:TR?= Mmj6V2FPT0WU
D-502MG NU\2U|BGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fVTWlEPTB;Nj60NlM4PiEQvF2= NH3KXVRUSU6JRWK=
LAN-6 Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPDVFdUUUN3ME22MlUyODJ|IN88US=> MWLTRW5ITVJ?
H-EMC-SS NIDWZnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL0fXdKSzVyPU[uOVYyPDdizszN M1zhXnNCVkeHUh?=
LC-2-ad NFrjUYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;VPGlEPTB;Nj62NFA4PiEQvF2= M3;p[XNCVkeHUh?=
NCI-H1693 MkPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TVTGlEPTB;Nj62NlIyPSEQvF2= MUjTRW5ITVJ?
SK-N-FI NIXmUFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjrTWM2OD14Lke1NFQ1KM7:TR?= NIHDPZdUSU6JRWK=
D-423MG M2fUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG3d4pKSzVyPU[uO|YyOTdizszN NGDJSXJUSU6JRWK=
KNS-42 M{f1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG5TWM2OD14Lke4NVk4KM7:TR?= NVXB[odGW0GQR1XS
GCT NX73RpBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTZwOUO4JO69VQ>? MYPTRW5ITVJ?
DSH1 NH3LZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTdwME[zN{DPxE1? NIPuS2tUSU6JRWK=
D-247MG NF75WZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvUW4s4UUN3ME23MlA4QDhzIN88US=> NWfwR4VTW0GQR1XS
NCI-SNU-5 M2PJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTdwMUizO|Eh|ryP NIXxUlNUSU6JRWK=
TE-6 NFS3UVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXLeIl3UUN3ME23MlIxPjBzIN88US=> NIXLOpNUSU6JRWK=
NOMO-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13tOWlEPTB;Nz6yNlEzPyEQvF2= NU\neZNmW0GQR1XS
NB17 M13lSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTdwM{CzNFkh|ryP NHHCSpdUSU6JRWK=
EW-22 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHITWM2OD15LkO0N|Q5KM7:TR?= MVjTRW5ITVJ?
EW-13 NUniOFJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljTTWM2OD15LkO1NVYzKM7:TR?= MoHnV2FPT0WU
DOHH-2 Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvkTWM2OD15LkS0NFIh|ryP NWPCToZJW0GQR1XS
TGBC1TKB NVTmdJIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;iTWM2OD15LkS5PFk6KM7:TR?= MmP0V2FPT0WU
GR-ST NX7QcodKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i5NWlEPTB;Nz61NlU6PCEQvF2= M2DW[XNCVkeHUh?=
KYSE-520 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTdwNUW1NVUh|ryP Mnz6V2FPT0WU
CAPAN-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzjTWM2OD15LkW5OVEh|ryP MknqV2FPT0WU
HCE-4 NVLldJEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTdwNkKyO|kh|ryP MkPFV2FPT0WU
MLMA NFT3ZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTdwNkK5OVch|ryP MmToV2FPT0WU
HT-144 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXm4XnR6UUN3ME23MlY2OzZ6IN88US=> Mmf0V2FPT0WU
KYSE-180 M3HvTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLJTWM2OD15LkexNVY6KM7:TR?= MlzJV2FPT0WU
TE-5 NXqyOFJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HmZmlEPTB;Nz65OVk4OSEQvF2= MnnmV2FPT0WU
IGROV-1 MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPMXnRKSzVyPUeuPVg2PTFizszN Mo[4V2FPT0WU
NCI-H1581 NIexV2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfSTWM2OD16LkCxNkDPxE1? M2TJXXNCVkeHUh?=
SW1990 MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzTTWM2OD16LkC0OlU6KM7:TR?= MW\TRW5ITVJ?
EFM-19 NGPCe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXwTWM2OD16LkC4OVQ2KM7:TR?= NH\ScnpUSU6JRWK=
OGR-1 NVjadIZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRThwNEOwNlMh|ryP NXL6OpJCW0GQR1XS
U-118-MG MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTxW4JKSzVyPUiuOFM1PjNizszN MlnuV2FPT0WU
SK-OV-3 NV;zb5VZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRThwNE[3OlUh|ryP MVTTRW5ITVJ?
KNS-62 NGKzVINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvQTWM2OD16LkWxO|YyKM7:TR?= MYfTRW5ITVJ?
GOTO NIT3XGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYq3NlBKUUN3ME24MlU4PjN3IN88US=> M4fhSnNCVkeHUh?=
8305C NELNNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXS4Snk3UUN3ME24MlcxPDh2IN88US=> NFfuXXFUSU6JRWK=
RPMI-2650 NFX5dVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRThwN{G5OVUh|ryP MWTTRW5ITVJ?
NEC8 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\GPWlEPTB;OD63OFMxPyEQvF2= MmLmV2FPT0WU
KYSE-450 NH;abFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXKyWWZ{UUN3ME24Mlg3PTR6IN88US=> NUDGWm13W0GQR1XS
RMG-I NH\qc3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PQfWlEPTB;OT6xOFA2QCEQvF2= M2\NVnNCVkeHUh?=
CAKI-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\OZlV{UUN3ME25MlMyQTd7IN88US=> NGS5O2tUSU6JRWK=
KYSE-510 NWnrUYFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjtTWM2OD17LkO1O|c5KM7:TR?= MnrDV2FPT0WU
A4-Fuk M4rSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTlwM{[3NFEh|ryP NV;4VpFQW0GQR1XS
AN3-CA NYPpRpFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3WTWM2OD17LkS1OFQ1KM7:TR?= MX;TRW5ITVJ?
SK-N-DZ NFe5TpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTlwN{K4OFkh|ryP MVTTRW5ITVJ?
HSC-2 MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTlwN{[2Nlkh|ryP NWPpZ3AzW0GQR1XS
EW-1 M{PYXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrMXIxKSzVyPUmuO|k{PjlizszN NW\Oc3RtW0GQR1XS
D-566MG M{W5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTlwOEO2OlQh|ryP NH;KN29USU6JRWK=
COLO-792 MnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L1NWlEPTB;OT65PFc1PiEQvF2= MWnTRW5ITVJ?
TE-10 M4TJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTFyLkCzPVYh|ryP NYH5PIF4W0GQR1XS
NCI-H650 NHLSXZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHvNVZKSzVyPUGwMlQzQDZizszN MXHTRW5ITVJ?
U-266 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFyLkS1OUDPxE1? MX;TRW5ITVJ?
Detroit562 MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTFzLkC1NVUh|ryP NXTDTlBJW0GQR1XS
NH-12 MlvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFzLkG0OFYh|ryP NFr6enhUSU6JRWK=
CO-314 M3;DVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DqTmlEPTB;MUGuNlg1OiEQvF2= MkX6V2FPT0WU
IST-MEL1 NHOzVJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrOVHRNUUN3ME2xNU42OzJ|IN88US=> MULTRW5ITVJ?
KNS-81-FD MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml33TWM2OD1zMT61OVI4KM7:TR?= NW\WNHZ1W0GQR1XS
SW1463 NXLFRXAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLyTWM2OD1zMT61PVg6KM7:TR?= NWnISWFxW0GQR1XS
NCI-H23 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXodHNMUUN3ME2xNU43PTV{IN88US=> M1vE[nNCVkeHUh?=
SK-MEL-2 NXvZbVF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7VNo1KSzVyPUGxMlcyQTdizszN M4foe3NCVkeHUh?=
NB13 NXLFS|ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjxeGlKSzVyPUGyMlE1QTVizszN M1z3WnNCVkeHUh?=
Daoy Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ficmlEPTB;MUKuNlg2PiEQvF2= M{\1fHNCVkeHUh?=
NCI-H1623 NVrlUHhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTF{LkO4NFEh|ryP M2TWcnNCVkeHUh?=
NMC-G1 Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m2e2lEPTB;MUKuO|E4KM7:TR?= MlzDV2FPT0WU
DK-MG MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTF{Lkm0PFIh|ryP M1zvVXNCVkeHUh?=
TCCSUP M1TYT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjBdplOUUN3ME2xN{4yOjh2IN88US=> Ml7OV2FPT0WU
SCC-15 MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjNUpRKSzVyPUGzMlI3PTFizszN NEDaVHRUSU6JRWK=
NOS-1 NHjWe2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLoSoNKSzVyPUGzMlI5QTNizszN NX\ocJlzW0GQR1XS
RH-1 NVnNRmFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELNZnpKSzVyPUGzMlMxOzdizszN NVfEc5B2W0GQR1XS
SK-MEL-3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXWOI9KSzVyPUGzMlM4OjhizszN MmrpV2FPT0WU
NB5 MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonoTWM2OD1zMz60NFY4KM7:TR?= M1rsbHNCVkeHUh?=
SNU-387 MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELQeFlKSzVyPUGzMlUxPzJizszN M1jOWnNCVkeHUh?=
CAL-120 MkCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF|Lk[3NVgh|ryP Mn\NV2FPT0WU
Mo-T MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3GyZ2lEPTB;MUOuO|A4KM7:TR?= M3;sOXNCVkeHUh?=
LNCaP-Clone-FGC M1e1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDxXmpJUUN3ME2xN{44QTl{IN88US=> MWTTRW5ITVJ?
CAN MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\XS|JKSzVyPUG0MlAzQDhizszN M1jUdnNCVkeHUh?=
SK-MEL-30 M1Lue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTF2LkC2N{DPxE1? MkDoV2FPT0WU
COLO-678 NUXmc3pvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF2LkC4NlIh|ryP NXvzeIM1W0GQR1XS
SCC-9 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\CUI5KSzVyPUG0MlExOjFizszN M1HYTXNCVkeHUh?=
KINGS-1 NXq0[nlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nZW2lEPTB;MUSuNVQxOiEQvF2= M3uzU3NCVkeHUh?=
SL-513 M2HXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzKR21uUUN3ME2xOE4yQDdizszN NVj2VXhrW0GQR1XS
HLE MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF2LkO4OVIh|ryP MYnTRW5ITVJ?
SW1573 M{jQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIL4SY9KSzVyPUG0MlQ1OzVizszN NI\zOmRUSU6JRWK=
KYSE-140 NHPIRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\2OIlGUUN3ME2xOE43OzJ5IN88US=> MkfaV2FPT0WU
SK-PN-DW M1LmVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF2LkiwNFEh|ryP MX;TRW5ITVJ?
A253 M32xU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF3LkC2NlUh|ryP MonMV2FPT0WU
CAL-12T MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3tTWM2OD1zNT60OlYzKM7:TR?= NF;ZcnBUSU6JRWK=
COLO-679 M4jGR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDKTWM2OD1zNT63Olg{KM7:TR?= NXPENWdzW0GQR1XS
UACC-257 M4jnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDHSIhKSzVyPUG2MlEzODFizszN NV\hbnM2W0GQR1XS
U-87-MG NXrpWplzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP1TWM2OD1zNj6zOVI{KM7:TR?= NHnlRVNUSU6JRWK=
HCC1806 NHX3Z2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTF4LkewO|Eh|ryP NHjMZ|dUSU6JRWK=
NCI-H2170 NWXkSpF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTRdlk3UUN3ME2xO{4zPDR6IN88US=> MomzV2FPT0WU
AGS MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv6R5JKSzVyPUG3MlM5ODhizszN M3nqOnNCVkeHUh?=
MEL-HO NFrzZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTF5Lke1NFMh|ryP NInVd5RUSU6JRWK=
SW48 NVLZ[VhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\veI9IUUN3ME2xO{44PzF4IN88US=> M2SxSXNCVkeHUh?=
HuP-T4 NEnrNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnizTWM2OD1zOD6wNlA3KM7:TR?= NWDIZXdLW0GQR1XS
NCI-H720 NXftNWM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXPTWM2OD1zOD6xOFAzKM7:TR?= MYrTRW5ITVJ?
RCC10RGB NEjPRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fPd2lEPTB;MUiuNVY6PyEQvF2= NU\iVWhRW0GQR1XS
HD-MY-Z NX7iW3lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTF6LkKyOVQh|ryP MkLnV2FPT0WU
A427 NIHEPItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2ftb2lEPTB;MUiuOVA6PCEQvF2= MVHTRW5ITVJ?
HCC2998 Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD5fJpKSzVyPUG4MlYxPTFizszN NX7lT|JjW0GQR1XS
EPLC-272H NXLCTnl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH6TWM2OD1zOT6wOFM1KM7:TR?= MWTTRW5ITVJ?
C32 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[5cmlEPTB;MUmuNFQ2KM7:TR?= M4HpSHNCVkeHUh?=
UMC-11 MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEn4fYVKSzVyPUG5MlIyOjNizszN MXnTRW5ITVJ?
CaR-1 Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfHTWM2OD1zOT62PFA1KM7:TR?= Mn\rV2FPT0WU
KYSE-410 NIXTeWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml61TWM2OD1zOT65NVM6KM7:TR?= NUSxbJFNW0GQR1XS
HuCCT1 NXXaOZNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTETWM2OD1{MD62Nlk1KM7:TR?= MWXTRW5ITVJ?
LB996-RCC M3z2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\CToxKSzVyPUKwMlcyPjhizszN M4HFXnNCVkeHUh?=
KYSE-70 MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TYXmlEPTB;MkCuPFA2QSEQvF2= NW\GTlJZW0GQR1XS
CAL-72 NIj2THhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJyLkmxOUDPxE1? MX\TRW5ITVJ?
Capan-2 MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Sw[2lEPTB;MkGuNFQyOyEQvF2= NW\qSJdwW0GQR1XS
PANC-08-13 NYXYXodqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnewTWM2OD1{MT6yOVE2KM7:TR?= MkK2V2FPT0WU
SBC-1 M4fHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X2UmlEPTB;MkGuN|A5OSEQvF2= NIXONotUSU6JRWK=
MFM-223 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrXTWM2OD1{MT6zN|QzKM7:TR?= MXfTRW5ITVJ?
BB49-HNC NVm2NHBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\neWZKSzVyPUKxMlU4OTZizszN NGX3fnJUSU6JRWK=
SH-4 NYnPN2NHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGX1PIxKSzVyPUKxMlY3OThizszN MV7TRW5ITVJ?
HuO9 NITSenBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHyTWM2OD1{MT65PFI2KM7:TR?= MU\TRW5ITVJ?
AM-38 M{XjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJ{LkC0PFUh|ryP MWHTRW5ITVJ?
A431 MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYKyNWhoUUN3ME2yN{4zOTF7IN88US=> MmfTV2FPT0WU
YAPC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJ|LkK2OVEh|ryP M3\kZnNCVkeHUh?=
LU-139 NGrkVHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJ|LkS4NFkh|ryP NXG0focxW0GQR1XS
HEC-1 M3Wwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjjfXhKSzVyPUKzMlQ6OzdizszN NIPkcZhUSU6JRWK=
SCC-25 M1vxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W3dGlEPTB;MkSuN|AxPiEQvF2= Mmi3V2FPT0WU
HT-29 NH3kZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGG2c|dKSzVyPUK0MlM5OjNizszN NULSXpU6W0GQR1XS
PC-14 M3LyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPsUHhKSzVyPUK0MlY2PzFizszN MlLKV2FPT0WU
Calu-6 NVzxe49kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUeyZW1YUUN3ME2yOU42ODdzIN88US=> MX\TRW5ITVJ?
SJRH30 Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L6VGlEPTB;MkWuOlQ6PiEQvF2= NYjxc2hYW0GQR1XS
ChaGo-K-1 M3v2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPyTWM2OD1{Nj6xOlI6KM7:TR?= NFvqN5JUSU6JRWK=
IA-LM M1vTbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3mPHBKSzVyPUK2MlM3PDVizszN NH\HSHFUSU6JRWK=
GP5d M{jJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrJTWM2OD1{Nj60OFkyKM7:TR?= M{Dkc3NCVkeHUh?=
NCI-H2291 M3PDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDkWHR{UUN3ME2yOk43PTRzIN88US=> NIniWnhUSU6JRWK=
BALL-1 NWHrRlQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJ4LkmzPVch|ryP M3vaXnNCVkeHUh?=
HCC1954 NHrxdZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUOwbG43UUN3ME2yOk46QDB6IN88US=> NGnKOJpUSU6JRWK=
NCI-H2452 NHmxOopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:wUGlEPTB;MkeuOFE3OyEQvF2= M3LRdnNCVkeHUh?=
LU-99A NXvSWJloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13jdmlEPTB;MkeuOVU5OiEQvF2= M{H4UXNCVkeHUh?=
NTERA-S-cl-D1 NGG0[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[yT45KSzVyPUK3MlczQTlizszN MXjTRW5ITVJ?
PANC-10-05 NX2zXFM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVuwZWE1UUN3ME2yO{44Pzd3IN88US=> MlnEV2FPT0WU
NCI-H2405 NFnKNnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVG1VHFkUUN3ME2yO{46Ozh5IN88US=> Mm\xV2FPT0WU
MDA-MB-415 MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXDSHJKSzVyPUK4MlQyOzdizszN NFTPW3pUSU6JRWK=
NCI-H2342 MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLrTWM2OD1{OD61NlgyKM7:TR?= NXjVb4Z3W0GQR1XS
TGBC24TKB MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPQRWxKSzVyPUK4MlcyOTdizszN MUXTRW5ITVJ?
LU-134-A NVqz[W1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[3[mlEPTB;MkiuPVI3OSEQvF2= NUHheHZsW0GQR1XS
SCC-4 M3v1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTNzLkC0PVQh|ryP MXjTRW5ITVJ?
Saos-2 NWXzfolxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nldGlEPTB;M{GuPVMxPiEQvF2= M1O5bnNCVkeHUh?=
RERF-LC-MS NYPKXJVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn73TWM2OD1|Mj64NlMyKM7:TR?= M1TpeHNCVkeHUh?=
M14 Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHyPWk1UUN3ME2zNk46PzZ2IN88US=> M1mwdXNCVkeHUh?=
HPAF-II M2rISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXNfHdtUUN3ME2zN{42ODFzIN88US=> NFO3THFUSU6JRWK=
NCI-H1755 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonQTWM2OD1|ND6zN|A2KM7:TR?= MlrBV2FPT0WU
D-392MG NVWzUoJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrH[HdKSzVyPUO1Mlg3PzRizszN NUj4WpM2W0GQR1XS
A704 MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTN4LkC0Nlch|ryP NWXaNZk{W0GQR1XS
CP50-MEL-B MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jyZWlEPTB;M{[uNVkyOSEQvF2= MXPTRW5ITVJ?
EW-18 MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEG0TIZKSzVyPUO2MlQ2OiEQvF2= M37Xb3NCVkeHUh?=
WM-115 NFSzToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\QOWlEPTB;M{[uPFA6QSEQvF2= M1[zNXNCVkeHUh?=
LU-65 MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTN5LkG0NVch|ryP MlTtV2FPT0WU
NCI-H1563 NFPSOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nM[GlEPTB;M{euNlQ5PCEQvF2= M4XFWnNCVkeHUh?=
DBTRG-05MG M4P4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPyTWM2OD1|OD6wOlkyKM7:TR?= NGL6RXJUSU6JRWK=
NCI-H630 NGXHPGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofBTWM2OD1|OD60O|E1KM7:TR?= MmH0V2FPT0WU
NCI-H1155 NIn0UXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjmPXNNUUN3ME2zPU4zPDJizszN NFuwb3RUSU6JRWK=
OVACR-3 M3n3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTK[VhZUUN3ME2zPU46OTl3IN88US=> NI\scWxUSU6JRWK=
OAW-42 NU\S[25DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTRyLkSyOVgh|ryP NUPybWRiW0GQR1XS
JVM-2 M{e3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTRzLkK0NVUh|ryP MWLTRW5ITVJ?
C3A M3\QZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTRzLkO0OFch|ryP MmG4V2FPT0WU
HT55 Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfITWM2OD12Mj6yPFQyKM7:TR?= M1LrSnNCVkeHUh?=
OVCAR-4 NVHYVJZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjBb5hKSzVyPUSyMlI6PzRizszN NHq4OIdUSU6JRWK=
MEG-01 NHL5O4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTR{LkS2NVYh|ryP MmTZV2FPT0WU
NCI-H82 M4jjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHHXWJ7UUN3ME20N{46QDl{IN88US=> NEjoNYpUSU6JRWK=
JEG-3 NVTRPG0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XMXGlEPTB;NESuPVQ4KM7:TR?= MYjTRW5ITVJ?
BPH-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XaNGlEPTB;NE[uN|k6QCEQvF2= NIfvZ4xUSU6JRWK=
MPP-89 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPYTWM2OD12Nz6yPFk5KM7:TR?= MoTMV2FPT0WU
ALL-PO M1jlVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrreI0xUUN3ME20O{41OTh6IN88US=> NGTSXI1USU6JRWK=
HT MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTR5LkS5NkDPxE1? NVvzclBFW0GQR1XS
NCI-H2347 NYPETHFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf3TWM2OD12OD6wO|E2KM7:TR?= NWXHUmwyW0GQR1XS
A2780 M4[3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLifotRUUN3ME20PU41OjJ6IN88US=> MYrTRW5ITVJ?
KARPAS-299 M{C0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe3N3Y5UUN3ME20PU42OTF7IN88US=> MmPYV2FPT0WU
NCI-H1651 NH7EbFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vQNWlEPTB;NEmuPFgzOSEQvF2= MmTsV2FPT0WU

多くの細胞株試験データを見る場合、クリックしてください

体内試験 PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
細胞試験:

[1]

+ 展開
  • 細胞株: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • 濃度: 0.01-1 μM
  • 反応時間: 24 hours
  • 実験の流れ:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • 製剤: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • 投薬量: 0-150 mg/kg
  • 投与方法: Given by gavage
    (参考用のみ)

溶解度 (25°C)

体外 Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
体内 順序で溶剤を入れること:
Saline
20 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 483.99
化学式

C24H29N7O2.HCl

CAS No. 827022-32-2
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT02907918 Not yet recruiting Breast Cancer|Cancer of Breast|Breast Carcinoma Washington University School of Medicine|Pfizer February 28, 2017 Phase 2
NCT01209598 Completed Sarcoma|Liposarcoma Memorial Sloan Kettering Cancer Center|Pfizer September 23, 2010 Phase 2
NCT03054363 Not yet recruiting Breast Cancer University of Colorado, Denver March 2017 Phase 1|Phase 2
NCT03024489 Not yet recruiting Head and Neck Cancer|Locally Advanced|Unresectable Mahidol University February 2017 Phase 1|Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    There are two kind of Palbociclibs available: the isethionate salt or the HCl salt. I would like to know which is the main difference between them and what are they more suitable for in terms of experiment type (cell culture or in vivo animals experiments).

  • 回答:

    This two compounds are different Palbociclib salt. S1579 is the Isethionate salt, and the S1116 is the HCl salt. you can use S1116 for oral administration while S1579 is more suitable for I.P. administration.

CDK信号経路図

CDK Inhibitors with Unique Features

相関CDK製品

Tags: Palbociclib (PD-0332991) HClを買う | Palbociclib (PD-0332991) HCl ic50 | Palbociclib (PD-0332991) HCl供給者 | Palbociclib (PD-0332991) HClを購入する | Palbociclib (PD-0332991) HCl費用 | Palbociclib (PD-0332991) HCl生産者 | オーダーPalbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl化学構造 | Palbociclib (PD-0332991) HCl分子量 | Palbociclib (PD-0332991) HCl代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID